Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
The main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver disease (NAFLD) or cirrhosis) with and without diabetes compared with healthy controls. The present study will contribute significantly to the understanding of the pathophysiology of liver disease and glucose metabolism. The final goal is that the results could pave the way for new treatment modalities for patients with liver disease.
Comparison of of insulin secretion (Area Under the Curve (AUC)) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.
I) Group 1: NAFLD patients with normal glucose tolerance Inclusion criteria
II) Group 2: NAFLD patients with type 2 diabetes Inclusion criteria
III) Group 3: NAFLD patients without type 2 diabetes Inclusion criteria
IV) Group 4: Cirrhosis with or without type 2 diabetes Inclusion criteria
V) Group 5: Healthy controls Inclusion criteria
Exclusion criteria (all groups)